Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2024-08-14 Regulatory Filings
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines
Regulatory Filings Classification · 100% confidence The document is an announcement titled "Nykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based Vaccines." It details the granting of a specific U.S. Patent (No. 12,059,459) and discusses its implications for the company's product VB10.NEO. This type of announcement, focusing on intellectual property protection (patents), does not fit neatly into standard financial reporting categories like 10-K, ER, or IR. It is a specific corporate action/update related to R&D and legal assets. Since there is no specific code for 'Patent Grant Announcement,' the most appropriate fallback category is 'Regulatory Filings' (RNS), as patent issuance is a formal regulatory event, or potentially 'LTR' (Legal Proceedings Report) if patents were viewed strictly as legal assets, but RNS is a better general fit for non-financial, non-management corporate news.
2024-08-14 English
Nykode Therapeutics – invitation to Q2 2024 financial results presentation
Earnings Release Classification · 98% confidence The document is a short announcement from Nykode Therapeutics stating that they will release their Q2 2024 financial results on August 21, 2024, and will host a subsequent webcast presentation. It explicitly mentions the release of the 'second quarter 2024 financial results' and provides details for the associated presentation/call. This structure—announcing the upcoming release of financial results and scheduling the associated call—is characteristic of an Earnings Release (ER) or, more precisely, an announcement *about* the upcoming earnings release. Since the document itself is not the full financial report (10-K or IR) nor the transcript of the call (CT), but rather the notification of the upcoming release and presentation, it fits best under the 'Earnings Release' category (ER) which covers the initial announcement of periodical financial results (key highlights). Alternatively, given it announces the publication of results, it could be RPA, but ER is more specific for scheduled earnings announcements. Given the focus on the upcoming 'financial results presentation', ER is the most appropriate fit over the general RPA. Q2 2024
2024-08-01 English
Nykode Therapeutics – invitation to Q2 2024 financial results presentation
Report Publication Announcement Classification · 99% confidence The document is a short announcement (3320 characters) explicitly stating that Nykode Therapeutics will release its Q2 2024 financial results on August 21, 2024, and will host a subsequent webcast presentation. It provides the date, time, and link for the webcast, and directs readers to the Investors section for the financial report. According to Rule #2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of a report, rather than being the report itself, should be classified as a Report Publication Announcement (RPA). It is not a full Earnings Release (ER) as it only announces the release date, not the results themselves.
2024-08-01 English
Nykode Therapeutics - Grant of share options
Director's Dealing Classification · 100% confidence The document text consists of structured tables detailing transactions involving financial instruments (stock options) by persons discharging managerial responsibilities (CEO, CFO, CSO) at Nykode Therapeutics ASA. Key phrases like 'Details of the person discharging managerial responsibilities', 'Reason for notification', 'Nature of the transaction: Acceptance of a stock option', and the reporting of specific dates and volumes strongly indicate a mandatory disclosure of insider trading or executive transactions. This aligns precisely with the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades).
2024-07-01 English
Nykode Therapeutics - Grant of share options
Remuneration Information Classification · 99% confidence The document text is very short (530 characters) and announces the 'Grant of share options' to employees and primary insiders. It explicitly states, 'Please see further details in attached document.' This structure—a brief announcement pointing to an attachment for full details—strongly suggests a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS), rather than the detailed report itself. Since the content specifically relates to the issuance of options/shares to insiders and employees, it is closely related to capital structure changes or insider transactions. However, the primary function of this short text is to announce the publication of the detailed information. Given the options, 'Share Issue/Capital Change' (SHA) covers the underlying event (granting options), but the format fits 'Report Publication Announcement' (RPA) best, as it is merely announcing the details are elsewhere. Since the grant of options is a specific type of capital/share activity, and this is a notification of that activity, SHA is a strong candidate. However, the 'MENU VS MEAL' rule prioritizes RPA for short announcements pointing to attachments. Since this is a notification about a transaction involving shares/options, and it's a brief announcement, I will lean towards the most specific category related to the transaction type, which is 'Share Issue/Capital Change' (SHA), as it details the grant itself, even if briefly. If the document were purely a regulatory form detailing the transaction, SHA would be correct. Given the brevity and the reference to an attachment, RPA is also plausible. Let's re-evaluate: Insider transactions (DIRs) are usually director dealings. This is an option grant to employees/insiders. SHA covers share issues/capital changes. Since option grants are a form of equity compensation/capital change, SHA is the most specific content classification. I will classify it as SHA, assuming the attached document contains the full details required for that filing type, and this is the summary announcement.
2024-07-01 English
Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 Meeting
Regulatory Filings Classification · 99% confidence The document is titled "Company Announcement" and details scientific advancements (updates on its Inverse Vaccine Platform) presented at a specific industry meeting (FOCIS 2024). It includes quotes from the CSO and CEO regarding future plans (establishing a subsidiary) and concludes with standard boilerplate information, contact details, and forward-looking statements. This format is characteristic of a press release announcing scientific or operational updates, rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive quarterly report (IR). Since it is an announcement of scientific progress and strategic intent, it fits best under the general category of Investor Relations material, but given the specific options, it is a general company announcement. It is not a proxy statement (DEF 14A), a dividend notice (DIV), or a major shareholding change (MRQ). It is most closely aligned with an Investor Presentation (IP) in terms of content focus (scientific data presentation), but the structure is that of a press release. Since there is no specific 'Press Release' or 'Corporate Update' code, and it is not a formal financial report, the most appropriate classification among the provided options for a general, non-financial-result-focused announcement is often the general Regulatory Filings/Announcements category (RNS), or if the content strongly suggests investor focus, Investor Presentation (IP). Given the detailed scientific updates and the context of presenting at a scientific meeting, it functions as an update for investors about R&D progress. However, the document itself is a press release announcing the presentation, not the presentation slides themselves. Therefore, RNS (Regulatory Filings/Announcements) serves as the best general fit for non-standard, non-financial-report announcements.
2024-06-20 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.